FIELD: chemistry.
SUBSTANCE: invention relates to novel glucagons-like peptide-1 (GLP-1) derivatives which have a prolonged activity profile, their pharmaceutical compositions and use of the compounds in preparing a medicinal agent for treating or preventing hyperglycemia, diabetes 2 or obesity. The compound is a therapeutic GLP-1 polypeptide bonded to a residue bonded with albumin through a hydrophilic separator.
EFFECT: higher effectiveness of derivatives and treatment method.
26 cl, 66 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ACYLATED GLP-1 COMPOUNDS | 2006 |
|
RU2434019C2 |
| DIPEPTIDE, CONTAINING NONPROTEINOGENIC AMINO ACID | 2012 |
|
RU2643515C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT | 2019 |
|
RU2804318C2 |
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
| SOLID COMPOSITIONS CONTAINING AGONIST TO GLP AND SALT OF N-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | 2011 |
|
RU2600440C2 |
| GLP-1 PEPTIDES COMPOSITIONS AND THEIR PRODUCTION | 2013 |
|
RU2641198C2 |
| GLP-1 ANALOGS | 1999 |
|
RU2288232C9 |
| ORAL DOSING OF GLUCAGON-LIKE PEPTIDE-1 COMPOUNDS | 2014 |
|
RU2671406C2 |
| DOUBLE ACYLATED GLP-1 DERIVATIVES | 2012 |
|
RU2602601C2 |
